Desensitization reduces some COVID-19-associated symptoms in minors with allergic rhinitis

Objective The aim of this study was to observe the symptoms after infection with coronavirus disease 19 (COVID-19) in minor and adult allergic rhinitis (AR) patients receiving different treatment therapies [Sublingual immunotherapy (SLIT) and conventional therapy]. Methods We recruited a total of 398 patients diagnosed with AR from the clinical system and divided them into AR-S, with AR-S1 representing individuals aged < 18 years of age, and AR-S2 those ≥ 18 years of age, and AR-C groups based on their treatment modalities. Between December 2022 and February 2023, we documented the respiratory symptoms and common manifestations of AR patients infected with the novel coronavirus. Results The AR-S1 group may be associated with a reduced risk of symptoms after infection including dry and itchy (OR = 0.373, 95%Cl:0.184–0.755), headache (OR = 0.385, 95%Cl:0.196–0.758), fatigue (OR = 0.376, 95%Cl:0.188–0.751), chest tightness (OR = 0.160, 95%Cl:0.049–0.522), and some symptoms after improvement of infection (cough, fatigue). Conclusion Minor AR patients with SLIT can reduce some of the symptoms in COVID-19-infected patients. Level of Evidence: 3